In the relentless quest to understand and conquer cancer, researchers have honed in on a new molecular frontier—Coenzyme Q10 (CoQ10) oxidoreductases and their pivotal role in ferroptosis, a unique form of programmed cell death distinguished by iron-dependent lipid peroxidation. The insight uncovered by Lee, Yoo, Kim, and colleagues, published in the June 2026 issue of Experimental & Molecular Medicine, unveils a complex interplay between redox homeostasis, cancer cell survival, and ferroptotic susceptibility, promising innovative therapeutic avenues that could revolutionize oncology.

CoQ10, a lipophilic molecule embedded within the inner mitochondrial membrane, functions fundamentally as an electron carrier in the mitochondrial respiratory chain. However, emerging evidence positions CoQ10 oxidoreductases as critical modulators of redox balance, influencing a cell’s propensity to undergo ferroptosis. Ferroptosis is characterized by iron-driven accumulation of lipid-based reactive oxygen species (ROS), disrupting cellular membranes and leading to an oxidative demise distinct from apoptosis or necrosis. This pathway has garnered attention for its potential to selectively target cancer cells resistant to conventional apoptosis-inducing therapies.

The research team deciphers how CoQ10 oxidoreductases exert a finely-tuned redox regulation, effectively governing ferroptotic sensitivity. These enzymes catalyze the reduction of CoQ10, sustaining its antioxidant capacity to mitigate lipid peroxidation. Intriguingly, certain cancers exhibit dysregulated expression or activity of these oxidoreductases, skewing the redox balance and fostering resistance against ferroptotic triggers. This mechanistic insight deepens our understanding of how cancer cells adapt to oxidative stress, potentially exploiting CoQ10 pathways to evade death.

A central revelation from the study is how CoQ10 oxidoreductase activity functions not only as a metabolic safeguard but also as a regulatory nexus controlling lipid peroxide detoxification. By reducing CoQ10, these enzymes replenish ubiquinol pools—powerful chain-breaking antioxidants that inhibit the propagation of lipid radicals in membranes. This antioxidative shield forms a biochemical barrier against ferroptotic induction, supporting cancer cell survival amid fluctuating oxidative milieus.

Ferroptosis has emerged as a compelling alternative to traditional apoptosis-centered therapies, particularly in malignancies exhibiting refractory resistance or mutated apoptotic machinery. The modulation of CoQ10 oxidoreductases, therefore, uncovers a therapeutic opportunity to sensitize tumors to ferroptotic death. Pharmacological inhibition or genetic suppression of these enzymes could dismantle the antioxidative defenses, augmenting lipid peroxidation and tipping the scales toward ferroptosis. Such strategies may offer a precision oncology approach, exploiting metabolic vulnerabilities while sparing normal tissues.

Adding complexity, the study highlights the context-dependent roles of different CoQ10 oxidoreductases isoforms across various cancer types. Some enzymes are upregulated, conferring enhanced ferroptosis resistance, whereas others might paradoxically promote oxidative stress under specific metabolic states. This heterogeneity accentuates the necessity for tailored therapeutic designs considering tumor-specific redox landscapes and CoQ10 enzymatic profiles.

Moreover, the researchers explore the cross-talk between CoQ10 oxidoreductases and other ferroptosis regulators, such as glutathione peroxidase 4 (GPX4) and membrane lipid remodeling enzymes. Inhibitory effects on CoQ10 oxidoreductases synergize with GPX4-targeting agents, generating combinatorial lethality that dismantles both lipid peroxide scavenging and detoxification pathways. This dual targeting could overcome resistance mechanisms and potentiate ferroptotic responses in challenging cancer subtypes.

Beyond its anti-ferroptotic functions, CoQ10 reduction by these oxidoreductases indirectly influences mitochondrial bioenergetics and ROS generation, highlighting an intricate feedback loop intertwining metabolic flux and redox signaling. As cancer cells often rewire mitochondrial dynamics to fuel aggressive phenotypes, manipulating CoQ10 oxidoreductase activity could disrupt cellular energetics, further sensitizing tumors to ferroptotic death.

The therapeutic implications of these findings are manifold. Small molecules modulating CoQ10 oxidoreductase activity offer a promising class of anticancer agents. Currently, several inhibitors are in preclinical evaluation, aiming to destabilize ubiquinol regeneration and collapse cellular redox defenses. Nanotechnology-enhanced delivery systems engineered to target tumors could also enhance drug specificity, reducing off-target effects and oxidative toxicity to healthy tissues.

Translationally, the elucidation of CoQ10 oxidoreductases as ferroptosis gatekeepers may provide prognostic biomarkers for patient stratification. Expression levels or enzymatic activity profiles could predict tumor susceptibility to ferroptosis-inducing therapies, enabling more personalized treatment regimens. Additionally, monitoring redox metabolites derived from CoQ10 pathways may serve as dynamic markers of therapeutic response.

Despite these advances, challenges remain in fully deciphering the intricate regulation of ferroptosis by CoQ10 oxidoreductases. Tumor microenvironment factors such as hypoxia, nutrient availability, and iron metabolism intricately modulate ferroptotic outcomes and CoQ10 enzyme function. Future studies must integrate multi-omic and spatial profiling to map these interactions comprehensively, paving the way for sophisticated intervention strategies.

In conclusion, the pioneering work of Lee and colleagues spotlights CoQ10 oxidoreductases as critical arbiters of ferroptotic cell death in cancer, functioning through redox regulation of lipid peroxide detoxification and cellular bioenergetics. Their dual role in shielding tumor cells and offering a therapeutic Achilles’ heel heralds a new chapter in redox biology and cancer therapy. As ferroptosis-based interventions advance toward clinical reality, targeting CoQ10 oxidoreductases emerges as a promising strategy to overcome drug resistance and improve patient outcomes in the relentless battle against cancer.

The implications of these findings extend beyond oncology, potentially informing therapeutic approaches for other diseases characterized by dysregulated redox homeostasis and lipid peroxidation, including neurodegeneration and cardiovascular disorders. The nuanced understanding of CoQ10 oxidoreductase function thus heralds broader biomedical significance, representing a cornerstone of future redox medicine.

Subject of Research:
CoQ10 oxidoreductases in ferroptosis regulation and cancer therapy

Article Title:
CoQ₁₀ oxidoreductases in ferroptosis and cancer: redox regulation and therapeutic opportunities.

Article References:
Lee, J., Yoo, I., Kim, M. et al. CoQ₁₀ oxidoreductases in ferroptosis and cancer: redox regulation and therapeutic opportunities. Exp Mol Med (2026). https://doi.org/10.1038/s12276-026-01736-w

Image Credits: AI Generated

DOI: 03 June 2026

The results were so promising one clinician started weeping.

Heather Jacene, MD, has assumed the prestigious role of president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), marking a significant milestone in the advancement of nuclear medicine and molecular imaging disciplines. Dr. Jacene’s appointment was announced during the SNMMI 2026 Annual Meeting held from May 30 to June 2 in Los Angeles, an event that gathers experts and pioneers driving innovation in precision medicine and molecular diagnostics. Her leadership is poised to catalyze new developments that integrate cutting-edge research with clinical practice, deepening the impact of molecular imaging technologies on patient outcomes.

In her multifaceted career, Dr. Jacene holds several prominent positions, including Chief of Molecular Imaging and Theranostics at Beth Israel Deaconess Medical Center, Clinical Director of Nuclear Medicine/PET-CT, and Senior Physician at Dana-Farber Cancer Institute. She also serves as Associate Professor of Radiology at Harvard Medical School. Her diverse roles underscore a strong commitment to pushing the boundaries of nuclear medicine through both clinical excellence and academic rigor, highlighting her capacity to bridge the gap between innovative research and patient-centered care.

One of Dr. Jacene’s primary objectives as president is to reinforce SNMMI as an indispensable resource for its members, spanning the spectrum from foundational basic science research to the highest standards of evidence-based clinical application. She emphasizes the critical importance of fostering an environment where nuclear medicine evolves through interdisciplinary collaboration and robust scientific inquiry, ensuring that the field remains at the forefront of diagnostic and therapeutic modalities.

Dr. Jacene is focused on creating dynamic platforms within SNMMI that encourage active participation and collaboration among members, transcending traditional disciplinary boundaries. By promoting multidisciplinary partnerships, she envisions expanding the reach and influence of nuclear medicine, driving innovations that enhance molecular imaging technologies such as PET-CT and radiopharmaceutical therapies. Her approach involves breaking down silos to facilitate knowledge exchange and accelerate technological advancements.

A major part of her agenda involves advocating for increased awareness and acceptance of nuclear medicine among clinical colleagues and patients alike. She aims to communicate the tangible benefits of these advanced imaging techniques in personalized medicine, emphasizing how molecular imaging enables precise characterization of disease states and therapeutic responses. This strategic communication will help solidify nuclear medicine’s role as a cornerstone of modern clinical practice.

Another critical challenge Dr. Jacene intends to address involves the barriers related to the availability, reimbursement, affordability, and funding of radiopharmaceuticals. These radiotracers are indispensable tools in targeted diagnostic and therapeutic procedures, yet their accessibility remains uneven. Her leadership will concentrate on policy advocacy and operational innovations to ensure broader and timely access to these vital agents, thus enhancing the clinical utility and patient reach of nuclear medicine.

Dr. Jacene’s extensive training and expertise reflect a career dedicated to nuclear medicine and molecular imaging. She earned her medical degree from the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School in New Brunswick, New Jersey. She subsequently completed both her residency and fellowship in nuclear medicine and PET-CT at Johns Hopkins University, Baltimore, where she honed her skills in cutting-edge diagnostic imaging techniques and the evolving applications of radiopharmaceuticals in oncology and beyond.

Her longstanding involvement with SNMMI is marked by significant leadership roles, including chairing the Scientific Program Committee, where she orchestrated innovative transformations to the Annual Meeting format. These changes have led to enhanced member engagement, increased networking opportunities, and a fertile ground for presenting novel research. She has also played a pivotal role in quality assurance, serving as Chair for the Quality of Practice Domain within the SNMMI Value Initiative, and helped establish the Radiopharmaceutical Centers of Excellence Program to standardize and elevate the delivery of radiopharmaceutical therapies.

Dr. Jacene’s research portfolio is both extensive and impactful, focusing predominantly on the application of FDG-PET/CT and other emerging PET tracers for the assessment of cancer biology and therapeutic efficacy. Her investigations delve into functional imaging biomarkers that reveal tumor metabolism, receptor expression, and microenvironmental changes, thereby informing more personalized and adaptive treatment strategies. Furthermore, she explores novel radiopharmaceutical therapies that promise to revolutionize the management of malignancies through targeted molecular interventions.

In addition to more than 100 peer-reviewed scientific publications, Dr. Jacene has authored numerous review articles and book chapters, contributing authoritative perspectives on the evolving landscape of molecular imaging and theranostics. Her scholarship not only advances academic discourse but also aids in translating complex imaging science into practical clinical guidelines and protocols that optimize patient care.

The new SNMMI leadership team for 2026-27 includes other distinguished figures such as Gary Ulaner, MD, PhD, FSNMMI, chosen as president-elect, and Jason S. Lewis, PhD, FSNMMI, as vice president-elect. The SNMMI Technologist Section has also elected Shannon Youngblood, EdD, MSRS, CNMT, RT(CT), as president, with Sara L. Johnson, CNMT, RT(N)(CT), serving as president-elect. Together, this leadership cadre represents a diverse spectrum of expertise poised to drive the society’s mission forward.

SNMMI remains a global scientific and medical organization dedicated to propelling nuclear medicine, molecular imaging, and theranostic precision medicine. Through its efforts, SNMMI facilitates innovations that allow clinicians to tailor diagnostic and therapeutic approaches to individual patients with unprecedented specificity, aiming for optimal outcomes. Dr. Jacene’s presidency symbolizes a sustained commitment to integrating high-caliber research, education, and clinical practice at the forefront of this transformative field.

Subject of Research:
Heather Jacene’s presidency at SNMMI and advancements in nuclear medicine and molecular imaging, including PET-CT innovations and radiopharmaceutical therapy.

Article Title:
Heather Jacene, MD, Named President of the Society of Nuclear Medicine and Molecular Imaging: Advancing the Future of Molecular Imaging and Theranostics

News Publication Date:
June 2026

Web References:
http://www.snmmi.org/

Image Credits:
Courtesy of SNMMI

Keywords:
Molecular imaging, Nuclear medicine, Positron emission tomography, Personalized medicine, Radiopharmaceutical therapy, Theranostics, FDG-PET/CT, Radiopharmaceutical Centers of Excellence, Precision medicine, SNMMI, Cancer imaging, Clinical molecular imaging